Turkey coronavirus (TCoV) infection continues to threaten turkey industry. Because specifi c treatment and effective vaccination program are not available, rapid and cost-effective detection of antibodies to TCoV infection is an important control measure to monitor the disease status in the fi elds. Two antibodycapture enzyme-linked immunosorbent assay (ELISA) procedures for detection of antibodies to TCoV are outlined in this chapter. One ELISA method uses chicken infectious bronchitis coronavirus (IBV) as the coating antigen based on antigenic cross-reactivity between TCoV and IBV. The other method relies on a recombinant TCoV nucleocapsid protein. Both methods are useful for serological diagnosis of TCoV infection in the turkey fl ocks.
Introduction
Turkey coronavirus (TCoV) causes an acute and highly contagious enteric disease affecting turkeys of all ages [ 1 , 2 ] . TCoV is an important pathogen and remains as a serious threat to the turkey industry. There is currently no specifi c treatment or effective vaccine for TCoV infection . In order to rapidly diagnose and effectively control turkey coronaviral enteritis , serological diagnosis of antibodies to TCoV becomes a critical tool to determine the infectivity of turkeys in the turkey fl ocks.
Immunofl uorescent antibody assay ( IFA ) for detection of anti-TCoV antibodies has been extensively used for disease outbreaks in the fi elds. However, IFA procedures are time consuming and labor intensive for handling large numbers of samples. In addition, IFA requires highly trained personnel to prepare frozen sections of turkey or turkey embryo intestines and perform fl uorescent microscopy.
ELISA method has high specifi city and sensitivity and can be applied to large numbers of samples simultaneously. Two ELISA procedures are highlighted in this chapter. One ELISA method utilizing infectious bronchitis virus (IBV) as a coating antigen for detection of antibody to TCoV is based on antigenic cross-reactivity between TCoV and IBV [ 3 ] . The other antibody-capture ELISA uses a recombinant TCoV nucleocapsid (N) protein as a coating antigen [ 4 , 5 ] .
Nucleocapsid protein appears to be the most abundant viral polypeptide in coronavirus infected cells during all stages of infection . Nucleocapsid protein is detected from 3 to 5 h after infection, at the same time or earlier than the other structural proteins. The only known posttranslational modifi cation of coronavirus N proteins is phosphorylation [ 6 ] . The coronavirus N protein is immunodominant [ 7 ] . Subcloning of the TCoV N gene to a prokaryotic expression system has resulted in a high-level induction of recombinant protein in our laboratory [ 4 ] . The recombinant TCoV N protein expressed from the prokaryotic system is expected to maintain its antigenic integrity because it is not glycosylated. 
Materials

Notes
1. Although incubation temperature at 37 °C is described for steps of blocking buffer, samples, and conjugate, incubation at room temperature can be a viable alternative when incubator with temperature control is not conveniently located. Please note that the overall assay reactivity (OD readings) will fl uctuate along with daily changes of room temperature. However, the end results of ELISA value (S/P ratio) as normalized by an appropriate positive control analyzed on the same plate will not be affected. It is better to keep a record of room temperature for possible trouble shooting when necessary.
2. In between and in the end of each wash cycle, it is important to tap-dry the plates on a stack of paper towel for lower nonspecifi c background reactivity.
ELISA with Recombinant TCoV N Protein as Coating Antigen
3. The commercially available ELISA plate coated with a pool of IBV strains including Massachusetts, JMK, Arkansas, Connecticut, Clone 30, D274, and D1466.
4. This blocking step is optional because the commercial dry plate is already blocked through the production process of commercial ELISA kits. The additional blocking step may help rehydrate the coating antigens in the wells before sample incubation step and subsequently enhance assay performance.
5. This wash step may be skipped if preferred. It is okay to add diluted samples after removal of the blocking buffer and tap dry the plate on a stack of paper towels. The presence of blocking buffer residue has limited effect on the next step for sample incubation. The components of blocking buffer including PBS buffer and BSA are also parts of the assay buffer in sample dilutions. This wash step is usually performed in our laboratory to achieve the best possible assay performance. Normal turkey sera: reactivity of normal turkey sera is consistently at low background signals in both ELISA methods, suggesting analytical variations. Cutoff point based on normal turkey sera does not refl ect biological variations and therefore is not functional. ELISA value normalization or cutoff point determination from signals of normal turkey sera is misleading.
Fix OD reading: a fi xed OD reading as cutoff point is not appropriate due to normal reading fl uctuations between batch runs, between analysts, between days, between laboratories.
Data normalization of raw OD readings with a suitable positive control sample is necessary for appropriate interpretation of unknown samples. Comparison of results from different laboratories is diffi cult due to the lack of standardized reagents. Data normalization with a standard source of PC may be a helpful factor to narrow down the comparability of results from different laboratories.
For system suitability (batch run acceptance criteria), three controls are recommended in each batch run. Each control is analyzed in duplicate ( N = 2; total four wells for two reportable values). Positive control serum is prepared in two levels at high positive control (HPC) and low positive control (LPC) and each analyzed in duplicates. Normal turkey serum is analyzed in duplicate as NC. Wells that contain all reagents except serum samples are nonspecifi c background (blank). The general acceptance criteria for these controls in each batch run are based on OD readings. At least two-thirds of controls should have readings in the following order: HPC > LPC > NC .
For data normalization, the reading of LPC is suggested in the calculation of ELISA value or S/P ratio of each test serum.
With a HPC in the calculation of S/P ratio in our laboratory, the optimum cutoff point is 0.18 for antibody-capture ELISA using IBV as the coating antigen , while the optimum cutoff point is 0.2 for ELISA using recombinant TCoV N protein as the coating antigen.
10. Coating buffers of various salts may be applied. Results are comparable with phosphate and carbonate based buffers. There are many different kinds of plates with different performance purpose. MaxiSorp ® plate gets consistent results for this ELISA method.
11. Coating overnight is minimum. Coating incubation over the weekend is routinely performed without noticeable impact to the assay. It is generally noted that incubation up to 5 days does not affect the ELISA results.
12. ELISA method with the recombinant TCoV N protein as coating antigen has higher reactivity than that with IBV as coating antigen. The dilution factors for serum samples and conjugates are adjusted accordingly. The minimum required dilution of serum samples is 1:800 for the assay with N protein compared to 1:40 for the assay with the IBV. The conjugate dilution factor is 1:10,000 for the assay with N protein compared to 1:1600 for the assay with the IBV.
13. Prevalence, sensitivity, specifi city, predictive values: The assay sensitivity and specifi city of both ELISA methods relative to IFA are considered comparable. With assumptions of relative sensitivity at 90 %, relative specifi city at 95 %, and disease prevalence at 55 %, positive predictive value (PPV) and negative predictive value (NPV) of these two ELISA methods are estimated below: 
